SARS-CoV-2 Seroprevalence in Relation to Timing of Symptoms

Ebinger, J.; Botwin, G. J.; Albert, C. M.; Alotaibi, M.; Arditi, M.; Berg, A. H.; Binek, A.; Botting, P.; Fert-Bober, J.; Figueiredo, J. C.; Grein, J. D.; Hasan, W.; Henglin, M.; Hussain, S. K.; Jain, M.; Joung, S.; Karin, M.; Kim, E. H.; Li, D.; Liu, Y.; Luong, E.; McGovern, D. P. B.; Merchant, A.; Merin, N.; Miles, P. B.; Nguyen, T.-T.; Raedschelders, K.; Rashid, M. A.; Riera, C. E.; Riggs, R. V.; Sharma, S.; Sobhani, K.; Sternbach, S.; Sun, N.; Tourtellotte, W. G.; Van Eyk, J. E.; Braun, J. G.; Cheng, S.

Of individuals with SARS-CoV-2 IgG antibody testing performed, those who contemporaneously experienced a cluster of Covid-19 relevant symptoms in the 1-2 months preceding the antibody assay were more likely to test positive whereas those who experienced the symptom clustering in the prior 3-6 months were more likely to test negative. These findings suggest that antibodies likely wane over a period of months, particularly in relation to the timing of symptoms.